



News Release

Cougar Biotechnology Announces Presentation at Rodman & Renshaw 3rd Annual Global Healthcare Conference

Los Angeles, CA, May 9, 2006 – Cougar Biotechnology, Inc, a publicly held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Tuesday, May 16th at 9:25 AM Central European Summer Time (CEST) at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.

A live webcast of the presentation can be accessed on the Company's website at www.cougarbiotechnology.com. The presentation will also be archived shortly after the live event and available online for 90 days following the conference.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme which is currently being tested in a Phase I clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

Contacts:

Alan H. Auerbach, Cougar Biotechnology, Inc.
+1 310 943 8040